Exelixis's SWOT analysis: stock poised for growth amid oncology pipeline progress

Exelixis (EXEL) reported strong Q1 2025 results, driven by its Cabozantinib franchise, leading to an increased full-year revenue guidance of $2.05B-$2.15B. The company's market position in Renal Cell Carcinoma (RCC) remains robust, with growth also expected from the recent Neuroendocrine Tumors (NET) launch. Key catalysts include pivotal readouts for Zanzalintinib, a potential successor to Cabozantinib, with analysts projecting peak sales of $5B by 2033, potentially transforming Exelixis into a multi-product oncology company.

Analysis

Exelixis, Inc. (EXEL) has demonstrated robust financial and operational performance, highlighted by a 106% stock return over the past year and an "EXCELLENT" financial health rating. The company reported strong Q1 2025 results, with its Cabozantinib (Cabo) franchise showing continued strength in Renal Cell Carcinoma (RCC) and gaining traction from the recent Neuroendocrine Tumors (NET) launch. This performance led to an upward revision of its full-year 2025 net product revenue guidance by $100 million to a range of $2.05 billion to $2.15 billion, implying approximately 10.8% growth at the midpoint compared to 2024. Exelixis achieved impressive revenue of $2.3 billion in the last twelve months, a 24.49% year-over-year increase, alongside an industry-leading gross margin of 96.78% and a healthy current ratio of 3.5. The company's perfect Piotroski Score of 9 indicates strong operational efficiency, and InvestingPro’s Fair Value analysis suggests EXEL is currently undervalued. Future growth is significantly tied to its pipeline, particularly Zanzalintinib (Zanza), a next-generation TKI positioned as a successor to Cabozantinib, with analysts projecting potential peak sales of $5 billion by 2033. Key upcoming catalysts in H2 2025 include pivotal readouts for Zanza from the STELLAR-303 (metastatic Colorectal Cancer) and STELLAR-304 (non-clear cell RCC) trials. Management anticipates Cabozantinib could reach $3 billion in U.S. sales by 2030, further supported by a recent legal victory extending its market exclusivity to 2030/2031. With approximately $1.75 billion in liquidity, Exelixis is well-positioned for strategic investments. However, risks include intense competition in the oncology market and the inherent uncertainties of clinical trial outcomes for its pipeline assets, particularly Zanzalintinib.

Key Decisions for Investors

• Given Exelixis's strong financial performance, raised guidance, and InvestingPro's assessment of undervaluation, investors might consider the stock favorably, particularly in light of its 106% return over the past year.
• Closely monitor the pivotal trial readouts for Zanzalintinib (STELLAR-303 and STELLAR-304) expected in the second half of 2025, as these are significant catalysts that could substantially impact the company's valuation and growth trajectory.
• Investors should weigh the substantial growth potential from Zanzalintinib and the expanding Cabozantinib franchise against the competitive oncology landscape and the binary risks associated with clinical trial success.